Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of ABP-671 in Hyperuricemia
NCT04060173Phase 1Completed
- Sponsor
- Atom Therapeutics
- Start
- Sep 2019
- Primary completion
- Dec 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hyperuricemia and gout comparing ABP-671 with Placebo (2 arms). Primary endpoint: Incidence of Adverse Events at 38 days. Started Sep 2019; status: completed.
02
Drugs
lingdolinurad
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on NCT04060173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04060173.